Takeda Pharmaceutical (TAK) said Thursday its experimental psoriasis medication zasocitinib outperformed competing drug deucravacitinib in a phase 3 clinical trial.
More than 35% of individuals given the daily oral therapy reached total skin clearance after 16 weeks, more than 2.5 times the response rate for deucravacitinib, the company said.
The trial met its primary and secondary endpoints while showing a safety profile consistent with prior research, and the company intends to submit a regulatory approval request within the fiscal year, Takeda said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments